Volume 10, Issue 4 (10-2020)                   Iran J Ped Hematol Oncol 2020, 10(4): 241-249 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mirbehbahani N B, Vaseghi G, Rashidbaghan A, Vakili A, Jahazi A. Comparison of Magnetic Resonance Imaging T2 Results in Beta-Thalassemia Patients Treated by Deferasirox or Combination of Deferoxamine and Deferiprone. Iran J Ped Hematol Oncol. 2020; 10 (4) :241-249
URL: http://ijpho.ssu.ac.ir/article-1-467-en.html
Gorgan Branch, Islamic Azad University, Gorgan, Iran
Abstract:   (197 Views)
Background: Iron extra load is an anticipated and lethal consequence of chronic blood transfusion in major beta-thalassemia patients; therefore it is necessary to use an efficient iron chelator drug to stimulate the evacuation of the surplus iron from the body. This trial was performed to compare myocardial and hepatic magnetic resonance imaging T2 (MRI T2*) results of beta-thalassemia patients treated by Deferasirox or combination of Deferoxamine and Deferiprone.
Material and Methods: In this clinical trial, 44 patients who were on combination therapy with Deferiprone and Deferoxamine and complied with the inclusion criteria were randomized to either case (Deferasirox) or control (combined therapy) groups. Twenty-two patients in the case group received Deferasirox. For 22 patients in the control group, prior treatment with Deferiprone and Deferoxamine was continued. Myocardial and hepatic MRI T2* results were assessed before and after the study. Moreover, serum ferritin level (SFL) was evaluated every 3 months.
Results: SFL at the start of the study did not differ significantly in two groups (2158.1± 1012.2 μg/L in the control group vs. 2145.5±1121.4 μg/L in the case group) (P=0.08). SFL at the end of the study did not differ significantly in two groups (2204.4±1143.5 μg/L in the control group vs. 2347.2±1236.6 μg/L in the case group), either (P=0.12). In each group, myocardial and hepatic MRI T2 at the start and at the end of the trial did not differ significantly (P>0.1).
Conclusion: Myocardial and hepatic MRI T2*results were better in the control (combination therapy) group than those in the case (Deferasirox) group. Major beta-thalassemia patients replied to combined treatment better than Deferasirox.
Full-Text [PDF 623 kb]   (84 Downloads)    
Type of Study: Research | Subject: Special
Received: 2020/05/15 | Accepted: 2020/08/8 | Published: 2020/10/19

Add your comments about this article : Your username or Email:

Send email to the article author

© 2021 All Rights Reserved | Iranian Journal of Pediatric Hematology and Oncology

Designed & Developed by : Yektaweb